Article
Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
Journal of the American College of Cardiology - 10 Jun 2014
Lambert Gilles, Petrides Francine, Chatelais Mathias, Blom Dirk J, Choque Benjamin, Tabet Fatiha, Wong Gida, Rye Kerry-Anne, Hooper Amanda J, Burnett John R, Barter Philip J, Marais A David
Abstract excerpt
OBJECTIVES: Do elevated proprotein convertase subtilisin/kexin type 9 (PCSK9) levels constitute an even greater risk for patients who already have reduced low-density lipoprotein receptor (LDLR) levels, such as those with heterozygous familial hypercholesterolemia (HeFH)? BACKGROUND: As a circula...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.